• 1
    Andersen K., Liljefors T., Gundertofe K., Perregaard J., Bogeso K.P. (1994) Development of a Receptor-Interaction Model for Serotonin 5-HT2A Receptor Antagonists. Predicting Selectivity with Respect to Dopamin D2 Receptors. J Med Chem;37:950962.
  • 2
    Davis K.L., Charney D., Coyle J.T., Nerneroff C. (2002) Neuropsychopharmacology: The Fifth Generation of Progress. New York: Raven Press.
  • 3
    Meltzer H.Y., Matsubara S., Lee J.C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamin D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther;251:238246.
  • 4
    Akash K.G., Balarama K.S., Paulose C.S. (2008) Enhanced 5-HT2A receptor status in the hypothalamus and corpus striatum of ethanol-treated rats. Cell Mol Neurobiol;28:10171025.
  • 5
    Hasselbalch S.G., Madsen K., Svarer C., Pinborg L.H., Holm S., Paulson O.B., Waldemar G., Knudsen G.M. (2008) Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging;29:18301838.
  • 6
    Herth M.M., Kramer V., Piel M., Palner M., Riss P.J., Knudsen G.M., Rösch F. (2009) Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem;17:29893002.
  • 7
    Rinaldi-Carmona M., Congy C., Santucci V., Simiand J., Gautret B., Neliat G., Labeeuw B., Le Fur G., Breliere J.C. (1992) Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. Pharmacol Exp Ther;262:759768.
  • 8
    Herth M.M., Debus F., Piel M., Palner M., Knudsen G.M., Lüddens H., Rösch F. (2008) Total synthesis and evaluation of [18F]MHMZ. Bioorg Med Chem Lett;18:15151519.
  • 9
    Herth M.M., Piel M., Debus P., Schmitt U., Lüddens H., Rösch F. (2009) Preliminary in vivo and ex vivo evaluation of the 5-HT2A imaging probe [18F]MH.MZ. Nucl Med Biol;36:447454.
  • 10
    Tan P.Z., Baldwin R.M., Van dyck C.H., Al-Tikriti M., Roth B., Khan N., Charney D.S., Innis R.B. (1999) Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. Nucl Med Biol;26:601608.
  • 11
    Ullrich T., Rice K.C. (2000) A Practical Synthesis of the Serotonin 5-HT2A Receptor Antagonist MDL 100907, its Enantiomer and their 3-Phenolic Derivatives as Precursors for [11C]Labeled PET Ligands. Bioorg Med Chem;8:24272432.
  • 12
    Tan P.Z., Baldwin R.M., Fu T., Charney D.S., Innis R.B. (1999) Rapid synthesis of F-18 and H-2 dual-labeled altanserin, a metabolically resistant PET ligand for 5-HT2A receptors. J Lab Comp Radiopharm;42:457467.
  • 13
    Villani F.J., Tavares R.F., Ellis C.A. (1969) Oximino ethers: dialkylaminoalkyl derivatives. J Pharm Sci;58:138.
  • 14
    Braden M.R., Parrish J.C., Naylor J.C., Nichols D.E. (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol;70:19561964.
  • 15
    Choudhary M.S., Craigo S., Roth B.L. (1993) A single point mutation (Phe340>Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. Mol Pharmacol;43:755761.
  • 16
    Dezi C., Brea J., Alvarado M., Ravina E., Masaguer C.F., Loza M.I., Sanz F., Pastor M. (2007) Multistructure 3D-QSAR studies on a series of conformationally constrained butyrophenones docked into a new homology model of the 5-HT2A receptor. J Med Chem;50:32423255.
  • 17
    Krass J.D., Jastorff B., Genieser H.G. (1997) Determination of Lipophilicity by Gradient Elution High-Performance Liquid Chromatography. Anal Chem;69:25752581.